Inhibidores de la aromatasa en el tratamiento adyuvante de pacientes postmenopáusicas con cáncer de mama. Metanálisis

The clinical studies evaluated show the consistent benefits of AIs at different adjuvant treatment stages; however, we have been unable to establish the optimum moment for their introduction due to the absence of direct comparisons between the different strategies. We now need to focus on the selection of patient sub-groups which could benefit from their use as a first-line therapy, the long-term toxicity of AIs, and their capacity to increase OS, regardless of the strategy followed, after a longer monitoring period. In light of the evidence available, bearing in mind certain limitations, we propose criteria for the use of AIs in daily clinical practice.